Loading stock data…
$17.03
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $20.73M↑ | $17.70M↓ | $45.89M↑ | $19.99M↓ | $26.20M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $1.84M↑ | -$5.85M↓ | $20.01M↑ | -$6.46M↓ | -$2.73M |
| Net Income | -$5.90M↓ | -$4.93M↓ | $61.02M↑ | $3.62M↓ | $54.84M |
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary dise...